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ABSTRACT 
 
Background: Adult cancer survivors often experience substantial psychological morbidity 
following the completion of acute cancer treatment. Unfortunately, current psychological 
interventions are of limited efficacy. This study explored if metacognitive therapy (MCT); a 
brief transdiagnostic psychological intervention was potentially efficacious and could be 
delivered effectively to adult cancer survivors with psychological morbidity. 
 
Method: An open trial with 3- and 6-months follow-up evaluated the treatment effects of 
MCT in 27 consecutively referred individuals to a clinical psychology health service 
specialising in psycho-oncology.   Each participant received a maximum of six 1-hour 
sessions of MCT.  Levels of anxiety, depression, fear of cancer recurrence, post-traumatic 
stress symptoms, health related quality of life, and metacognitive beliefs and processes were 
assessed using self-report questionnaires.  
 
Results: MCT was associated with statistically significant reductions across all outcome 
measures which were maintained through to 6 months follow-up. In the ITT sample on the 
primary treatment outcome measure, the Hospital Anxiety and Depression Scale-Total, 59% 
of participants met recovery criteria at post treatment and 52% at 6 months follow-up, 
respectively   No participants significantly deteriorated.  In the completer sample (N=20), 80% 
recovered at post-treatment and 70% at 6 months follow-up.   MCT was acceptable to patients 
with approximately 75% of patients completing all treatment sessions. 
 
Conclusion: MCT, a brief transdiagnostic psychological intervention can be delivered 
effectively to a heterogenous group of cancer survivors with promising treatment effects.  
Examining the efficacy of brief MCT against the current gold standard psychological 
intervention would be a valuable advance towards improving the quality of life of cancer 
survivors. 
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INTRODUCTION 1 
 2 
The incidence of cancer in the UK is projected to increase by 2% over the next 15 years with 3 
survival rates also increasing.  It is estimated that survival rates have doubled over the past 40 4 
years with a ten-year survival rate of approximately 50% (Cancer Research UK, 2017).  in 5 
2016, there were an estimated 15.5 million cancer survivors which is expected to increase to 6 
20.3 million by 2026 (National Cancer Institute, 2018).   Psychological morbidity is common 7 
in cancer survivors. Approximately 25% of cancer survivors have clinically significant levels 8 
of anxiety and depression that could benefit from treatment (Hoffman, 2009).  Posttraumatic 9 
stress disorder symptoms are common in cancer survivors with estimates ranging from 6% to 10 
45% (Swartzman et al., 2016).   Fear of cancer recurrence (FCR) is highly prevalent, a 11 
systematic review concluded that almost 60% of cancer survivors experience debilitating FCR 12 
(Simard & Savard, 2015).   Psychological morbidity adversely impacts ongoing cancer care by 13 
reducing attendance at follow up screening appointments (DiMatteo, Lepper & Croghan, 2000; 14 
Thewes et al., 2014), health related quality of life (Lemasters et al., 2013) and increases 15 
healthcare costs (Carlson & Butz, 2004; Jansen, et al., 2016) and use of healthcare services 16 
(Elliot et al., 2011). 17 
 18 
The substantial prevalence and associated problems with psychological morbidity in cancer 19 
survivors requires effective interventions. Unfortunately, highly efficacious psychological 20 
interventions are unavailable (Demoncada & Feurstein, 2006; Rehse & Pukrop, 2003; Faller et 21 
al., 2013).   The most widely evaluated and recommended psychological intervention is 22 
cognitive behavioural therapy (CBT) but it may be that core components of CBT; labelling 23 
cognitive distortions and reality testing negative automatic thoughts (NATs) are clinically 24 
limited where NATs will frequently reflect accurate thoughts about cancer recurrence and 25 
morbidity (Greer et al., 2010, Cook et al., 2015a). An intervention which does not need to focus 26 
on the content of cognition i.e. NATs, but instead focuses on core psychological processes 27 
underpinning psychological morbidity may be more efficacious for cancer survivors.   28 
 29 
Metacognitive therapy (MCT; Wells, 2009) offers an alternative psychological approach to the 30 
treatment of psychological morbidity in cancer survivors. MCT is derived from a trans-31 
diagnostic theory of psychopathology, the Self-Regulatory Executive Function (S-REF) model 32 
(Wells & Matthews, 1994, 1996).  The model states that psychological morbidity becomes 33 
persistent when people use the cognitive-attentional syndrome (CAS) in response to unwanted 34 
thoughts.  The CAS has three broad main components; (i) perseveration (worry,  rumination, 35 
over-analysing, repeatedly questioning one’s thoughts); (ii) attentional strategies (a heightened 36 
focus on possible signs of threat which can be internal e.g. signs of anxiety or external e.g. 37 
reminders of cancer); and (iii) unhelpful coping strategies (e.g. searching the internet for 38 
positive outcomes  by cancer survivors, avoidance of reminders of cancer).   39 
 40 
The S-REF model states that perseveration is guided by positive metacognitive beliefs about 41 
the helpfulness of worry and rumination: e.g. “worry will help me be better prepared”, worry 42 
will ensure that I complete my daily tasks”. Unfortunately, worry and rumination achieve the 43 
opposite, because the person experiences more negative thoughts and views more situations as 44 
potentially dangerous. The individual repeatedly acts as if unwanted negative thoughts are 45 
meaningful which leads to the development of an inflexible way of responding to thoughts. A 46 
more flexible response style can help to alleviate perseveration. Similarly, the S-REF model 47 
specifies that threat monitoring (e.g. scanning for symptoms or for negative thoughts) is 48 
determined by positive metacognitive beliefs.  More specifically, a person comes to believe 49 
that scanning the environment or one’s mind and/or body for symptoms will reduce distress 50 
whereas it leads to the persistence of threat and distress. Furthermore, negative metacognitive 51 
beliefs about the uncontrollability and danger of worry sustain and increase worry.  Modifying 52 
negative metacognitive beliefs is fundamentally important in the S-REF model because, if 53 
patients believe that worry is uncontrollable, they will not attempt to control it.  Therefore, it 54 
is possible that through targeting metacognitive beliefs and processes rather than cognitive 55 
content, MCT offers a particularly close ‘fit’ with the needs of cancer survivors indicating 56 
potential for greater efficacy (McNicol et al., 2013). 57 
 58 
The development of MCT for psychological morbidity in cancer is evolving with encouraging 59 
evidence for the explanatory and therapeutic utility of MCT. There is increasing evidence for 60 
the role of metacognitive beliefs and processes in emotional distress in cancer survivors from 61 
cross-sectional and prospective studies (Butow, et al., 2015; Thewes, Bell, & Butow, 2013; 62 
Cook et al., 2014, Cook et al., 2015a; Cook et al., 2015b; Fisher et al., 2018 and in adult cancer 63 
patients undergoing chemotherapy( Quantropani et al., 2016; Quatropnai, Lenzo, & Filastro, 64 
2017).  There have been two tests of the potential efficacy of MCT in cancer survivor. First, an 65 
open trial of MCT for emotional distress in adolescent and young adult cancer survivors found 66 
clinically significant reductions in anxiety, depression and posttraumatic stress symptoms 67 
(Fisher et al., 2015). Second, a multiple baseline study of MCT in four adult cancer survivors 68 
(Fisher, Byrne, & Salmon, 2017) reported substantial reduction in anxiety, depression and fear 69 
of cancer recurrence over six one-hour sessions These studies illustrate that MCT can rapidly 70 
alleviate psychological morbidity in cancer patients but before progressing to a randomised 71 
controlled trial, further evidence of the potential efficacy and feasibility of delivering MCT is 72 
required.  The present study therefore examined if MCT delivered over six one-hour individual 73 
treatment sessions would result in clinically significant improvements in anxiety, depression, 74 
posttraumatic stress symptoms, fear and cancer recurrence and overall quality of life 75 
immediately following treatment and over a six-month follow-up period. The study also 76 
examined if MCT would be associated with reductions in the metacognitive beliefs and 77 
processes.   78 
Materials and Method 79 
 80 
Design 81 
An open trial with follow-up at 3 and 6 months evaluated the potential efficacy of brief MCT 82 
for adult survivors of cancer experiencing emotional distress.  Data was also gathered on 83 
recruitment and retention rates. Ethical approval was provided by the National Health Service 84 
North West Research Ethics Committee (reference 15/NW/0820). 85 
 86 
Participants and procedure 87 
Potentially suitable participants were identified from consecutive referrals to an adult clinical 88 
heath psychology service which specialises in psychological interventions for cancer patients.  89 
Those patients with elevated scores on the Hospital Anxiety and Depression Scale (HADS; 90 
Zigmond & Snaith, 1983) and indicated a willingness to be approached for possible 91 
participation in an intervention were provided with an information sheet about the study.  Those 92 
patients were contacted and invited to attend an assessment appointment to determine their 93 
suitability for inclusion.   Following the informed consent procedure, clinical and demographic 94 
data was obtained by interview and participants completed a range of questionnaires assessing 95 
the severity of psychological morbidity (see section on measures).  Participants also completed 96 
all questionnaires at posttreatment, and again at 3- and 6-months follow-up.  All questionnaires 97 
were returned to an independent assessor who scored and entered the data.   98 
 99 
Twenty seven cancer survivors participated in the study and met the following inclusion 100 
criteria: i) a score of >15 on the Hospital Anxiety and Depression Scale-Total (HADS-T); ii) 101 
had been diagnosed with cancer ≥6 months previously; iii) were aged 18 years or over; iv) had 102 
completed acute medical treatment for cancer (i.e. chemotherapy, radiotherapy, surgery); v) 103 
were not receiving concurrent psychological treatment; vi) were not actively suicidal; vii) 104 
reported no current substance use; vii) were not experiencing a psychotic or organic illness; 105 
viii) were free from psychotropic medication or has been on  a stable dose for at least 8 weeks; 106 
and (viiii) were able to speak and understand English. 107 
 108 
Intervention 109 
MCT was delivered over a maximum of 6 individual face-to face sessions that were 45-60 110 
minutes in duration. The intervention followed a manualized protocol (Wells, 2009).  As the 111 
intervention was transdiagnostic, MCT followed the same protocol for each patient in the study 112 
regardless of symptom presentation.  In session 1, the formulation template used when 113 
treating depression served as the basis for the development of an idiosyncratic case formulation 114 
for each participant, thus following the approach adopted in previous evaluations of MCT for 115 
cancer survivors (McNicol et al., 2013; Fisher et al., 2015; Fisher, Byrne, Salmon, 2017).  The 116 
next step in treatment is socialization which proceeds by sharing the case formulation and by 117 
Socratic Questioning to help the patient understand that each aspect of the CAS and several 118 
types of metacognitive beliefs are maintaining emotional distress. MCT then focuses on 119 
modifying negative beliefs about uncontrollability of rumination/worry through training in 120 
detached mindfulness (DM) and in rumination/worry postponement (Wells, 2009). Patients are 121 
helped to understand how naturally occurring thoughts (e.g. “I’m useless”, “What if my cancer 122 
comes back?”, “My family will not be able to cope”) do not necessarily lead to perseveration.). 123 
Rumination/worry postponement is a behavioural experiment to challenge the negative 124 
metacognitive belief that perseveration is an uncontrollable process. Positive metacognitive 125 
beliefs about the helpful nature of worry/rumination and the other unhelpful coping responses 126 
are also highlighted to the patients and addressed. Final sessions address relapse prevention 127 
and involve modifying remaining use of the ‘cognitive attentional syndrome’, reviewing any 128 
remaining conviction in positive and negative metacognitive beliefs and consolidating and 129 
alternative ways of responding to negative thoughts. Three therapists delivered MCT (PF, AB 130 
and LF).  Supervision was provided by PF on a weekly basis.  131 
 132 
Measures  133 
Hospital Anxiety Depression Scale (HADS; Zigmond and Snaith, 1983) 134 
The HADS is a 14-item self-report questionnaire measuring anxiety and depression (seven 135 
items each) over the past week. Each item is rated on a 4-point scale (0–3). Scores for each 136 
subscale range from 0 to 21 with higher scores reflecting more sever anxiety or depression. 137 
Scores of 11 or more on each of the subscales indicate caseness.  Combining the two subscales 138 
provides a measure of emotional distress.  The HADS-Total is the “gold standard” outcome 139 
measure for evaluating the efficacy of interventions on emotional distress in cancer 140 
populations, and has excellent psychometric properties (Luckett et al., 2010). 141 
 142 
Impact of Events Scale-Revised (IES-R; Weiss, 2007) 143 
The IES-R is a 22-item self-report questionnaire measuring trauma-related symptoms The total 144 
scale score ranges from 0 to -88 with higher scores indicative of more severe trauma symptoms. 145 
A total score of ≥ 33 indicates a probable diagnosis of PTSD (Weiss, 2007).  The IES-R is 146 
validated for use in cancer populations with good psychometric properties (Salsman et al., 147 
2015). 148 
 149 
 150 
 151 
Fear of Cancer Recurrence Inventory (FCRI; Simard & Savard, 2009) 152 
The FCRI is 42-item self-report questionnaire assessing 7 aspects of FCR. Each item is rated 153 
on a 5-point scale (0-4).   A total score for the FCRI is obtained by summing scores on the 7 154 
subscales, with higher scores indicating greater severity (range 0-168).   The FCRI is the most 155 
validated measure of FCR across a wide range of cancer types (Simard & Savard, 2009). 156 
 157 
Functional Assessment of Cancer Therapy-General (FACT-G; Cellla et al., 1993) 158 
The FACT-G is a 27 item self-report questionnaire that measures four domains of health-159 
related quality of life (HRQOL).  Each item is rated on a 5-point scale from 0 (not at all) to 4 160 
(very much).  The FACT-G total score ranges from 0-108 with higher scores indicating a better 161 
HRQOL.  The FACT-G has been used extensively in mixed cancer populations and has 162 
excellent psychometric properties (Brucker et al., 2005) 163 
 164 
Metacognitions Questionnaire-30 (MCQ-30; Wells & Cartwright-Hatton, 2004). 165 
The MCQ-30 measures 5 domains of metacognition by 30 items. Participants rate the extent to 166 
which they “generally agree” with statements presented on a 4-point scale from 1 (do not agree) 167 
to 4 (agree very much), providing total scores for each subscale ranging from 6 to24. Higher 168 
scores indicate greater conviction in metacognitive beliefs. The MCQ-30 assesses: (1) positive 169 
beliefs about worry, (2) negative beliefs uncontrollability and danger of worry, (3) cognitive 170 
confidence, (4) beliefs about the need to control thoughts, and (5) cognitive self-consciousness.  171 
The MCQ-30 has been validated for use in cancer patients (Cook et al., 2014) 172 
 173 
Cognitive Attentional Scale-1 (CAS-1; Wells, 2009)  174 
The CAS-1 is a 10 item self-report questionnaire that assesses metacognitive processes and 175 
beliefs.   Items 1 to 6 assess the fundamental components of the CAS (perseverative thinking, 176 
threat monitoring and unhelpful coping strategies) Each item is rated on a 10-point scale from 177 
0 (none of the time) to 100 (all the time).  Items 7 to 10 assess metacognitive beliefs and are 178 
not reported in the present study.  To provide an overall measure of the CAS, the 6 items were 179 
summed and divided by the number of items.  The same method has been used previously 180 
(Heffer-Rahn & Fisher, 2018; Fisher, Reilly, & Noble, 2018). 181 
  182 
Statistical Analyses  183 
Intention to treat (ITT) analyses were used to determine the potential efficacy of brief MCT for 184 
emotional distress in cancer survivors. Missing data for the non-completers in the study were 185 
replaced by using the last observation carried forward (LOCF) method.   The LOCF has been 186 
considered a conservative approach when evaluating treatment outcomes in open trials.  187 
Treatment effects across time (pretreatment, posttreatment, and 3-and 6-month 188 
follow-up) were assessed with repeated-measures analysis of variance (ANOVA); the 189 
Greenhouse–Geisser correction was applied when the assumption of sphericity was violated.  190 
Main effects were followed by Bonferroni-adjusted pairwise comparisons for each outcome 191 
measure. Within group effect sizes were calculated using Cohen’s d to assess the magnitude of 192 
treatment effects from pretreatment to post-treatment and from pre-treatment to both 3 month 193 
and 6-month follow-ups.  To determine the clinical significance of treatment effects the 194 
methodology developed by Jacobson and colleagues (Jacobson, Follette, & Revenstorf, 1984, 195 
Jacobson & Truax,1991) was applied to the HADS-Total.  Each patient can be allocated to one 196 
of four treatment outcomes: reliable deterioration, no change, reliable improvement, or 197 
recovered. The first three outcomes are calculated using from the Reliable Change Index (RCI), 198 
which determines whether the magnitude of change is statistically significant.  Data to calculate 199 
the RCI was drawn from a large non-clinical sample (Crawford et al., 2001).  The cut-off score 200 
for the HADS-Total was ≤ 13 determined using “criterion a” To be classified as recovered, 201 
patients must demonstrate reliable change and their posttreatment or follow-up scores must be 202 
below the cut off score.  The data were analysed using SPSS version 24. 203 
 204 
Results 205 
 206 
Participant characteristics 207 
Forty-three consecutive referrals were identified as potentially eligible.  There were 16 patients 208 
who did not enter the study; 10 did not wish to participate, 3 did not attend the assessment 209 
interview 1 patient did not have a have a cancer diagnosis, 1 patient did not meet the threshold 210 
for severity of distress with a HADS-T score of less than 16 and 1 patient had a recurrence of 211 
cancer. 212 
 213 
Twenty-seven patients began the trial of whom 20 completed treatment; a completion rate of 214 
74%.   Of the seven patients who did not complete the six sessions of MCT; three patients 215 
attended only one session, two patients 2 sessions, one patient 3 sessions and the final patient 216 
attended 4 sessions but sporadically and decided that it was not feasible to continue therapy. 217 
Reasons for non-completion were; one patient was hospitalised for cancer recurrence, one 218 
participant stopped therapy to be able to provide full time care for a relative, 2 participants did 219 
not wish to undertake psychological therapy and 3 patients dropped out without providing a 220 
reason.  The demographic and clinical characteristics of the sample shown in Table 1.  It is 221 
notable that 96% of the sample met casesness for anxiety with 93% also scoring above the 222 
clinical cut-off for PTSD. Additionally, 8 of the 27 patients had experienced a cancer 223 
recurrence, none of these patients discontinued MCT.  224 
 225 
Treatment effects 226 
There were significant main effects of time on all outcome measures (Table 2). Follow-up 227 
Bonferroni pairwise comparisons demonstrated significant differences from pre-treatment to 228 
post-treatment, and from pre-treatment to 3-and 6-month follow up on all outcome measures 229 
indicating that treatment effects were maintained. Overall, there was significant improvement 230 
across all symptom and quality of life measures and significant reductions in metacognitive 231 
beliefs (MCQ-30) and processes (CAS-1). 232 
 233 
Effect size estimates  234 
Within group effect sizes for the ITT sample are shown in Table 3. There are large pre to post 235 
treatment effect sizes across all outcome measures (0.83 -1.66). There are comparable effect 236 
sizes across all measures at both follow-up timepoints illustrating that the magnitude of 237 
treatment effects is maintained from post-treatment to 6-months follow-up. 238 
 239 
Clinically significance of treatment 240 
In the ITT sample, most participants were recovered on the HADS-Total at post-treatment and 241 
across the follow-up period.  In terms of the proportion of patients that responded to treatment, 242 
81% were improved at post-treatment and 74% at 6-months follow-up.  Examination of the 243 
recovery rates for those patients that completed treatment shows recovery rates of 80% at post-244 
treatment and 70% at 6-months follow-up. A summary of the clinical significance of treatment 245 
outcomes is shown in Table 4. 246 
 247 
Discussion 248 
This study provides further support for the potential of brief MCT to alleviate psychological 249 
morbidity in cancer survivors.  Following six 1-hour sessions of  MCT, there were significant 250 
reductions in anxiety depression, post-traumatic stress symptoms, fear of cancer recurrence 251 
and improvements in quality of life.  There were also significant reductions in metacognitive 252 
beliefs and the cognitive attentional syndrome as predicted by the metacognitive model (Wells 253 
& Matthews, 1994, 1996).  Treatment gains were sustained across all measures of 254 
psychological morbidity and metacognitive beliefs and processes through to six-months 255 
follow-up.  The practical significance as opposed to the statistical significance of the results 256 
was assessed using the Jacobson approach to clinical significance. In those patients who 257 
completed brief MCT, there were very high recovery rates on the primary outcome variable 258 
assessing the severity of general distress; 80% of patients were recovered following six one-259 
hour sessions of individually delivered MCT.  The recovery rate of 70% at six months follow-260 
up suggests that the effects of the intervention persist beyond treatment completion.  Brief 261 
MCT appeared acceptable to cancer survivors with approximately 75% of participants starting 262 
treatment completed treatment.  It is possible that the treatment completion rate can be 263 
improved and early drop-outs from treatment prevented by ensuring patients are more 264 
effectively socialised to the aims of MCT. 265 
 266 
The within group effect sizes on FCR provide the opportunity to benchmark the effects of brief 267 
MCT with those reported in recent randomized controlled trial (Butow et al., 2017) evaluating 268 
an integrative approach for FCR.  The psychological treatment in the trials conducted by 269 
Butow and colleagues evaluated an intervention (ConquerFear) based on the treatment 270 
components drawn from three theoretical frameworks; common sense model (Levanthal, 271 
Diefenbach, & Levanthal, 1993) the self-regulatory model (Wells & Matthews, 1994) and 272 
relational frame theory (Hayes et al., 2006).    Although the ConquerFear intervention was 273 
more efficacious than an attention control condition, the within group effect size for FCR from 274 
pre to post treatment was 0.77.  This compares to a within group effect size of 1.66 in the 275 
present study.  Although, the present study had a much smaller sample size thereby limiting 276 
the generalizability of this finding. However, unlike the ConquerFear study, our open trial 277 
included participants with depression and severe trauma symptoms indicative of PTSD.  278 
Developing specific interventions for each aspect of psychological morbidity for cancer 279 
survivors may be unnecessary and integrating treatment components from theoretically 280 
inconsistent models could “dilute” treatment efficacy and compromise therapist training 281 
(Wells & Fisher, 2015; Byrne, Salmon, & Fisher, 2018).   282 
 283 
The present open trial is a valuable step in the translation of MCT from adult mental health 284 
populations to cancer survivors and is following the recommended framework for translating 285 
psychological interventions to a new population (Medical Research Council UK, 2008).  The 286 
limitations of open trials are well known but should not undermine their place in treatment 287 
development research (Medical Research Council UK, 2008).  No data was collected on 288 
either treatment adherence or therapist competency beyond that achievable through weekly 289 
supervisory sessions.  Subsequent studies should include independent assessment of both 290 
treatment adherence and therapist competency to increase confidence in the conclusions 291 
drawn and that any treatment effects were attributable to MCT. 292 
 293 
A comparatively small sample was used, but the sample appeared representative of cancer 294 
survivors referred to the clinical health psychology service.  Other limitations include the 295 
lack of ethnic diversity and that most of the sample were female, thereby compromising 296 
external validity. Treatment outcome was assessed exclusively by self-report questionnaires 297 
in the present study.  Although exclusive reliance on self-report questionnaires could be 298 
considered a methodological weakness, the study was not focused on changes psychiatric 299 
diagnosis, rather the study was designed to measure general distress for which the “gold 300 
standard” outcome measure for evaluating the efficacy of interventions on emotional distress 301 
in cancer was used (Luckett et al., 2010). 302 
Overcoming other limitations of open trials can be achieved through conducting randomised 303 
controlled evaluation.  It would be valuable to assess the hypothesised mechanisms of 304 
change in the context of an RCT against the current recommended treatment approaches, it 305 
may be that the treated patients who recover change to most on metacognitive variables 306 
regardless of the treatment received. There were statistically significant reductions in all 307 
metacognitive beliefs and the CAS over treatment, which were maintained through to the six 308 
months follow up assessment.  This study adds to the extant literature that MCT has the 309 
potential to be an efficacious psychological intervention for adult cancer survivors.  Given 310 
the limited outcomes of currently available interventions, there is an obvious need to conduct 311 
a controlled evaluation of the potential of brief MCT to alleviate psychological morbidity in 312 
cancer survivors. 313 
 314 
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Table 1. Participant characteristics 336 
 337 
 338 
  339 
 Mean (SD) Range 
Age  51.15 (11.67)  29-67 
Age at time of cancer diagnosis 46.71 (10.99)  28-64 
Months since completion of acute medical treatment  25.81 (27.93)  3-142 
  
N 
Gender  
 Female 23 
 Male  4 
Ethnicity  
 White Caucasian 26 
             Asian 1 
Cancer Diagnosis  
 Breast 13 
 Haematological 6 
 Ovarian 3 
 Sarcoma 2 
 Colorectal 1 
 Ocular  1 
 Lung 1 
Cancer Treatment  
 Chemotherapy, radiotherapy, and surgery 8 
 Chemotherapy plus surgery 5 
 Chemotherapy alone 4 
 Surgery alone  3 
 Chemotherapy, plus radiotherapy 2 
 Radiotherapy plus surgery 1 
 Radiotherapy alone 1 
 Other/not reported 3 
Employment Status  
 Employed 13 
 Unemployed 14 
Education Level  
 School level or higher 
 No qualifications 
26 
1 
Relationship Status  
 Married/cohabiting 11 
 Live alone 16 
Psychotropic Medication  
 Current taking 11 
 Previously taken 5 
 Never taken 11 
Previous Psychological Treatment   
 Yes 17 
 No 10 
Distress Outcomes   
 Anxiety (HADS-A >11) 26 (96%) 
 Depression (HADS-D>11) 12 (44%) 
 PTSD symptoms (IES-R >33) 25 (93%) 
Table 2. Means, standard deviations (in parentheses) and repeated measures analysis of variance for outcome measures: 340 
    Intention-to-Treat Sample (n = 27). 341 
 342 
 343 
Measure 
Pre-
treatment  
Post-treatment  3-months follow-up 6-months follow-up  F (df)  
HADS -Total 25.04 (5.65) 12.70 (9.61) 13.00 (9.99) 12.67 (10.12)  39.76 (2.15, 56.05)  p<.0001 
HADS - Anxiety 14.44 (3.51) 7.85 (5.14) 7.96 (5.49) 7.52 (5.44)     32.85 (2.21, 57.30) p<.0001 
HADS - Depression 10.74 (3.77) 4.81 (4.79) 5.04 (4.89) 5.15 (5.23)     31.60 (2.03, 52.71) p<.0001 
IES-R -Total 53.15 (16.43) 26.04 (26.93) 27.92 (26.64) 27.81 (25.35)  26.56 (2.32, 60.28) p<.0001 
FCRI- Total             108.29 (22.18) 59.59 (38.84) 63.37 (36.63) 63.81 (36.73) 34.42 (1.49, 38.48) p<.0001 
FACT-G-Total 54.33 (14.94) 76.87 (20.16) 74.55 (21.63) 74.94 (22.73) 31.09 (2.21, 57.43) p<.0001 
MCQ-30 Positive beliefs 11.74 (4.66) 8.22 (3.73) 8.29 (3.61) 8.33 (3.89) 9.47 (1.48, 38.53) p<.001 
MCQ-30 Negative beliefs  18.59 (3.27) 11.85 (5.23) 12.03(5.21) 11.70 (5.04) 28.87 (1.78, 46.28) p<.0001 
MCQ-30 Cognitive confidence 15.74 (5.28) 11.41 (4.98) 12.48 (5.61) 11.77 (5.58) 13.35 (2.18, 55.06) p<.0001 
MCQ-30 Need for control 14.41 (4.38) 10.07 (4.73) 9.33 (4.72) 9.26 (4.77) 23.30 (1.40, 36.40) p<.0001 
MCQ-30 Cognitive self-consciousness 17.93 (3.98) 12.66 (6.09) 12.52 (4.87) 12.59 (5.15) 23.85 (2.27, 59.05) p<.0001 
CAS-1 55.25 (19.19) 20.06 (25.85) 20.86 (26.19) 24.32 (28.61 44.67 (2.18, 56.69) p<.0001 
 344 
Note. df, degrees of freedom; HADS, Hospital Anxiety and Depression Scale; IES-R, Impact of Event Scale-Revised; FCRI, Fear of Cancer Recurrence Inventory; FACT-G, 345 
Functional Assessment of Cancer Therapy-General; MCQ-30, Metacognitions Questionnaire-30; CAS-1, Cognitive Attentional Scale. 346 
 347 
Table 3. Within group effect sizes (Cohen’s d) for outcome measures at post-treatment 348 
    and 3- and 6-months follow-up 349 
 350 
 Post-treatment 
3-months 
follow-up 
6-months  
follow-up 
HADS-Total 1.56 1.48 1.51 
HADS-Anxiety 1.49 1.41 1.51 
HADS-Depression 1.37 1.31 1.23 
IES-R Total 1.21 1.14 1.18 
FCRI-Total 1.66 1.48 1.46 
FACT-G-Total -1.27 -1.09 -1.07 
MCQ-30 Positive beliefs 0.83 0.83 0.79 
MCQ-30 Negative beliefs 1.51 1.50 1.62 
MCQ-30 Cognitive confidence 0.84 0.59 0.75 
MCQ-30-Need for control 0.95 1.12 1.12 
MCQ-30-Congnitive self-consciousness 1.02 1.22 1.16 
CAS-1 1.55 1.49 1.27 
 351 
Note: HADS, Hospital Anxiety and Depression Scale; IES-R, Impact of Event Scale-Revised; FCRI, 352 
Fear of Cancer Recurrence Inventory; FACT-G, Functional Assessment of Cancer Therapy-General; 353 
MCQ-30, Metacognitions Questionnaire-30; CAS-1, Cognitive Attentional Scale. 354 
Table 4. Clinical significance outcomes on HADS-Total 355 
 356 
 Post treatment 3-months follow-up 6-months follow-up 
 No change Improved Recovered Deteriorated No change Improved Recovered No change Improved Recovered 
ITT 
(n=27) 
5 
19% 
5 
19% 
17 
62% 
1 
5% 
4 
25% 
8 
17% 
14 
58% 
7 
26% 
5 
19% 
15 
56% 
Completers 
(n= 20) 
1 
20% 
3 
0% 
16 
80% 
1 
5% 
0 
0% 
6 
30% 
13 
65% 
3 
15% 
3 
15% 
14 
70% 
 357 
Note: ITT: intention to treat sample; Completers: treatment completers sample 358 
 359 
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